摘要
目的评价川芎嗪注射液辅助治疗冠心病心绞痛的疗效及安全性。方法系统检索CNKI、VIP、万方医学网和PubMed,筛选出发表在科技核心期刊中的以观察在常规用药基础上加用川芎嗪对改善不稳定型心绞痛症状或心电图的随机对照试验。结果根据标准共纳入11篇文献。与对照组相比,川芎嗪组治疗冠心病心绞痛的临床显效率的OR=1.91,95%CI(1.43,2.54),P<0.01;心电图显效率的OR=2.10,95%CI(1.53,2.90),P<0.01。主要不良反应为皮疹、头痛、头晕、恶心和乏力,症状轻微。结论在常规治疗基础上,川芎嗪注射液是一种安全的、能够进一步增强治疗冠心病心绞痛疗效的辅助药物。但由于本系统评价纳入研究的证据强度不高,故上述结论尚需更多高质量随机对照试验来进一步验证。
Objective It is to evaluate the clinical efficacy and safety of ligustrazine injection in the treatment of angina pectoris of patients with coronary artery disease. Methods Published article of core journals reporting the use of ligustrazine in the treatment of the above disease on the top of routine care were collected by a comprehensive literature search of major database such as CNKI, VIP, WanFang Data, PubMed. Results According to the inclusion criteria, eleven studies were included in this recta-analysis. The pooled effects of the recta-analysis showed that the ligustrazine was able to effectively improve the clinical symptoms （OR=1.91,95% CI（1.43,2.54）, P 〈0.01） and electrocardiography （OR =2.10, 95% CI（1.53, 2.90） ,P 〈 0.01 ） when compared with control groups. The main drug-related side effects included rash, headache, dizziness, digust and fatigue. However, these symptoms were slight and did not affect the continuous therapy. Conclusion Ligustrazine is a safe additional therapeutic for angina pectoris. The use of ligustrazine on the basis of standard therapy can make patients receive more beneficial effects compared with routine therapy alone. Further high quality of randomized controlled trials are required to provide reliable evidence on the treatment of patients with angina pectoris.
出处
《现代中西医结合杂志》
CAS
2014年第8期810-812,818,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
川芎嗪
冠心病
心绞痛
系统评价
ligustrazine
coronary artery disease
angina pectoris
meta-analysis
